Clinics in Dermatology
Volume 24, Issue 5 , Pages 374-392 , September 2006

Systemic and localized scleroderma

  • Lorinda Chung, MD

      Affiliations

    • Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • Co–primary authors.
    • ,
  • Jan Lin, MD

      Affiliations

    • Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095-1670, USA
    • Co–primary authors.
    • ,
  • Daniel E. Furst, MD

      Affiliations

    • Division of Rheumatology, Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, CA 90095-1670, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 310 794 9504; fax: +1 310 206 8476.
    • Co–senior authors.
    • ,
  • David Fiorentino, MD

      Affiliations

    • Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
    • Co–senior authors.

References 

  1. Peterson L, et al. The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol. 1997;24:73–80
  2. Provost T, Greenberg A, Falanga V. Localized cutaneous sclerosis. In:  Sontheimer R,  Provost T editor. Cutaneous manifestations of rheumatic diseases. Philadelphia: Lippincott Williams & Wilkins; 2004;p. 125–134
  3. Prescott R, Freemont AJ, Jones CJ, Hoyland J, Fielding P. Sequential dermal microvascular and perivascular changes in the development of scleroderma. J Pathol. 1992;166:255–263
  4. Hasegawa M, Sato S, Takehara K. Augmented production of chemokines (monocyte chemotactic protein–1 (MCP-1), macrophage inflammatory protein–1alpha (MIP-1alpha) and MIP-1beta) in patients with systemic sclerosis: MCP-1 and MIP-1alpha may be involved in the development of pulmonary fibrosis. Clin Exp Immunol. 1999;117:159–165
  5. Kowalewski C, et al. Alterations of basement membrane zone and cutaneous microvasculature in morphea and extragenital lichen sclerosus. Am J Dermatopathol. 2005;27:489–496
  6. Kahaleh M. The role of vascular endothelium in the pathogenesis of connective tissue disease: endothelial injury, activation, participation and response. Clin Exp Rheumatol. 1990;8:595–601
  7. Zulian F. Systemic manifestations in localized scleroderma. Curr Rheumatol Rep. 2004;6:417–424
  8. Hasegawa M, et al. Serum levels of tumor necrosis factor and interleukin-13 are elevated in patients with localized scleroderma. Dermatology. 2003;207:141–147
  9. Jinnin M, et al. Serum levels of manganese superoxide dismutase in patients with localized scleroderma. Exp Dermatol. 2004;13:357–360
  10. Liu B, Connolly M. The pathogenesis of cutaneous fibrosis. Semin Cutan Med Surg. 1998;17:3–11
  11. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor beta receptors in dermal fibroblasts in skin sections from patients with localized scleroderma. Arthritis Rheum. 2001;44:731–734
  12. Tuffanelli D. Localized scleroderma. Semin Cutan Med Surg. 1998;17:27–33
  13. Weide B, Walz T, Garbe C. Is morphoea caused by Borrelia burgdorferi? A review. Br J Dermatol. 2000;142:636–644
  14. O'Leary P, Nomland R. Clinical study of 103 cases of scleroderma. Am J Med Sci. 1930;180:95–112
  15. Peterson L, Nelson A, Su W. Classification of morphea (localized scleroderma). Mayo Clin Proc. 1995;70:1068–1076
  16. Cannick L, et al. Nodular scleroderma: case report and literature review. J Rheumatol. 2003;30:2500–2502
  17. Rencic A, Brinster N, Nousari C. Keloid morphea and nodular scleroderma: two distinct clinical variants of scleroderma?. J Cutan Med Surg. 1999;7:20–24
  18. Jablonska S, Blaszczyk M. Is superficial morphea synonymous with atrophoderma Pasini-Pierini?. J Am Acad Dermatol. 2004;50:979–980[author reply 980]
  19. McNiff J, et al. Morphea limited to the superficial reticular dermis: an underrecognized histologic phenomenon. J Am Acad Dermatol. 1999;21:315–319
  20. Rencic A, et al. Bullous lesions in scleroderma. Int J Dermatol. 2002;41:335–339
  21. Zulian F, et al. Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum. 2005;52:2873–2881
  22. Soma Y, Fujimoto M. Frontoparietal scleroderma (en coup de sabre) following Blaschko's lines. J Am Acad Dermatol. 1998;38(2 Pt 2):366–368
  23. Orozco-Covarrubias L, et al. Scleroderma 'en coup de sabre' and progressive facial hemiatrophy. Is it possible to differentiate them?. J Eur Acad Dermatol Venereol. 2002;16:361–366
  24. Menni S, Marzano A, Passoni E. Neurologic abnormalities in two patients with facial hemiatrophy and sclerosis coexisting with morphea. Pediatr Dermatol. 1997;14:113–116
  25. Appenzeller S, et al. Neuroimaging findings in scleroderma en coup de sabre. Neurology. 2004;62:1585–1589
  26. Su W, Person J. Morphea profunda. A new concept and a histopathologic study of 23 cases. Am J Dermatopathol. 1981;3:251–260
  27. Shulman L. Diffuse fasciitis with eosinophilia: a new syndrome?. Trans Assoc Am Physicians. 1975;88:70–86
  28. Doyle JA, Ginsburg WW. Eosinophilic fasciitis. Med Clin North Am. 1989;73:1157–1166
  29. Khanna D, Verity A, Grossman J. Eosinophilic fasciitis with multiple myeloma: a new haematological association. Ann Rheum Dis. 2002;61:1111–1112
  30. Aberer E, Klade H, Hobisch G. A clinical, histological, and immunohistochemical comparison of acrodermatitis chronica atrophicans and morphea. Am J Dermatopathol. 1991;13:334–341
  31. Falanga V, Medsger T. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol. 1987;17:648–656
  32. Falanga V, et al. Linear scleroderma. Clinical spectrum, prognosis, and laboratory abnormalities. Ann Intern Med. 1986;104:849–857
  33. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder. Rheumatology. 2005;44:274–279
  34. Mimura Y, et al. Rheumatoid factor isotypes in localized scleroderma. Clin Exp Dermatol. 2005;30:405–408
  35. Hayakawa I, et al. Anti-DNA topoisomerase IIalpha autoantibodies in localized scleroderma. Arthritis Rheum. 2004;50:227–232
  36. Arnett F, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum. 1999;42:2656–2659
  37. Christianson H, et al. Localized scleroderma; a clinical study of two hundred thirty-five cases. A.M.A. Arch Dermatol. 1956;74:629–639
  38. Hulshof M, et al. Double-blind, placebo-controlled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Am Acad Dermatol. 2000;43:1017–1023
  39. Hunzelmann N, et al. Double-blind, placebo-controlled study of intralesional interferon gamma for the treatment of localized scleroderma. J Am Acad Dermatol. 1997;36(3 Pt 1):433–435
  40. Mancuso G, Berdondini R. Localized scleroderma: response to occlusive treatment with tacrolimus ointment. Br J Dermatol. 2005;152:180–182
  41. Cunningham B, et al. Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol. 1998;39(2 Pt 1):211–215
  42. Dytoc M, et al. First case series on the use of imiquimod for morphoea. Br J Dermatol. 2005;153:815–820
  43. Kerscher M, et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol. 1998;38:21–26
  44. de Rie M, et al. Evaluation of medium-dose UVA1 phototherapy in localized scleroderma with the cutometer and fast Fourier transform method. Dermatology. 2003;207:298–301
  45. Camacho N, et al. Medium-dose UVA1 phototherapy in localized scleroderma and its effect in CD34-positive dendritic cells. J Am Acad Dermatol. 2001;45:697–699
  46. Kreuter A, et al. Combined treatment with calcipotriol ointment and low-dose ultraviolet A1 phototherapy in childhood morphea. Pediatr Dermatol. 2001;18:241–245
  47. El-Mofty M, et al. Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. PhotodermatolPhotoimmunol Photomed. 2004;20:148–156
  48. Stege H, et al. High-dose UVA1 radiation therapy for localized scleroderma. J Am Acad Dermatol. 1997;36(6 Pt 1):938–944
  49. El-Mofty M, et al. Low-dose broad-band UVA in morphea using a new method for evaluation. Photodermatol Photoimmunol Photomed. 2000;16:43–49
  50. Kerscher M, et al. PUVA bath photochemotherapy for localized scleroderma. Evaluation of 17 consecutive patients. Arch Dermatol. 1996;132:1280–1282
  51. Joly P, et al. Treatment of severe forms of localized scleroderma with oral corticosteroids: follow-up study on 17 patients. Arch Dermatol. 1994;130:663–664
  52. Falanga V, Medsger T. D-penicillamine in the treatment of localized scleroderma. Arch Dermatol. 1990;126:609–612
  53. Seyger M, et al. Low-dose methotrexate in the treatment of widespread morphea. J Am Acad Dermatol. 1998;39(2 Pt 1):220–225
  54. Uziel Y, et al. Methotrexate and corticosteroid therapy for pediatric localized scleroderma. J Pediatr. 2000;136:91–95
  55. Kreuter A, et al. Pulsed high-dose corticosteroids combined with low-dose methotrexate in severe localized scleroderma. Arch Dermatol. 2005;141:847–852
  56. Elst E, Van Suijlekom-Smit L, Oranje A. Treatment of linear scleroderma with oral 1,25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol. 1999;16:53–58
  57. Caca-Biljanovska N, et al. Treatment of generalized morphea with oral 1,25-dihydroxyvitamin D3. Adv Exp Med Biol. 1999;455:299–304
  58. Fisher G, Kang S. Phototherapy for scleroderma: biologic rationale, results, and promise. Curr Opin Rheumatol. 2002;14:723–726
  59. Cribier B, et al. Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. Dermatology. 1995;191:25–31
  60. Romano C, et al. Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. J Eur Acad Dermatol Venereol. 2003;17:10–13
  61. Clements PJ, Furst D. Systemic sclerosis. 2nd ed.. Philadelphia: Lippincott Williams and Wilkins; 2004;
  62. Furst DE, et al. Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study. Arthritis Rheum. 1989;32:584–593
  63. Clements P, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42:1194–1203
  64. Steen VD, et al. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med. 1984;76:779–786
  65. Arnett FC, et al. Increased prevalence of systemic sclerosis in a Native American tribe in Oklahoma. Association with an Amerindian HLA haplotype. Arthritis Rheum. 1996;39:1362–1370
  66. Arnett FC, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44:1359–1362
  67. Mayes M, Reveille JD. Epidemiology, demographics and genetics. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 1–15
  68. Reveille JD, et al. HLA-DPB1 alleles and autoantibody subsets in systemic lupus erythematosus, Sjogren's syndrome and progressive systemic sclerosis: a question of disease relevance. Tissue Antigens. 1992;40:45–48
  69. Reveille JD, et al. Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma). J Clin Invest. 1992;89:1208–1213
  70. Nelson JL. Microchimerism and HLA relationships of pregnancy: implications for autoimmune diseases. Curr Rheumatol Rep. 2001;3:222–229
  71. Artlett CM. Microchimerism and scleroderma: an update. Curr Rheumatol Rep. 2003;5:154–159
  72. Christner PJ, et al. Increased numbers of microchimeric cells of fetal origin are associated with dermal fibrosis in mice following injection of vinyl chloride. Arthritis Rheum. 2000;43:2598–2605
  73. Jimenez SA, Artlett CM. Microchimerism and systemic sclerosis. Curr Opin Rheumatol. 2005;17:86–90
  74. Hamamdzic D, et al. MCMV induces neointima in IFN-gammaR−/− mice: intimal cell apoptosis and persistent proliferation of myofibroblasts. BMC Musculoskelet Disord. 2001;2:3
  75. Ohtsuka T, Yamazaki S. Increased prevalence of human parvovirus B19 DNA in systemic sclerosis skin. Br J Dermatol. 2004;150:1091–1095
  76. Parks CG, Conrad K, Cooper GS. Occupational exposure to crystalline silica and autoimmune disease. Environ Health Perspect. 1999;107(Suppl 5):793–802
  77. Haustein UF, Anderegg U. Silica induced scleroderma—clinical and experimental aspects. J Rheumatol. 1998;25:1917–1926
  78. Ihn H. Pathogenesis of fibrosis: role of TGF-beta and CTGF. Curr Opin Rheumatol. 2002;14:681–685
  79. Ihn H, et al. Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor beta receptors. Arthritis Rheum. 2001;44:474–480
  80. Kucich U, et al. Transforming growth factor-beta stabilizes elastin mRNA by a pathway requiring active Smads, protein kinase C-delta, and p38. Am J Respir Cell Mol Biol. 2002;26:183–188
  81. Schachna L, Wigley FM. Targeting mediators of vascular injury in scleroderma. Curr Opin Rheumatol. 2002;14:686–693
  82. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am. 1996;22:675–694
  83. Abraham DJ, et al. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am J Pathol. 1997;151:831–841
  84. Hitraya EG, et al. Identification of elements in the promoter region of the alpha1(I) procollagen gene involved in its up-regulated expression in systemic sclerosis. Arthritis Rheum. 1998;41:2048–2058
  85. Zhang W, et al. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)–collagen (COL1A2) transcription. J Biol Chem. 2000;275:39237–39245
  86. Medsger TA. Systemic sclerosis (scleroderma): clinical aspects. In:  Koopman WJ editors. Arthritis and allied conditions: a textbook of rheumatology. Philadelphia: Lippincott Williams and Wilkins; 2000;p. 1590–1624
  87. LeRoy EC, Medsger TA. Raynaud's phenomenon: a proposal for classification. Clin Exp Rheumatol. 1992;10:485–488
  88. Steen VD, Medsger TA. The palpable tendon friction rub: an important physical examination finding in patients with systemic sclerosis. Arthritis Rheum. 1997;40:1146–1151
  89. Clements PJ, et al. Muscle disease in progressive systemic sclerosis: diagnostic and therapeutic considerations. Arthritis Rheum. 1978;21:62–71
  90. Rose S, Young MA, Reynolds JC. Gastrointestinal manifestations of scleroderma. Gastroenterol Clin North Am. 1998;27:563–594
  91. Weinstein WM, Kadell BM. The gastrointestinal tract in systemic sclerosis. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 293–308
  92. Schuffler MD, Beegle RG. Progressive systemic sclerosis of the gastrointestinal tract and hereditary hollow visceral myopathy: two distinguishable disorders of intestinal smooth muscle. Gastroenterology. 1979;77(4 Pt 1):664–671
  93. Steen VD, et al. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113:352–357
  94. Steen VD, Medsger TA. Epidemiology and natural history of systemic sclerosis. Rheum Dis Clin North Am. 1990;16:1–10
  95. Steen V. Renal involvement in systemic sclerosis. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 279–292
  96. Traub YM, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983;62:335–352
  97. Tuffanelli DL, Winkelmann RK. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol. 1961;84:359–371
  98. Livi R, et al. Renal functional reserve is impaired in patients with systemic sclerosis without clinical signs of kidney involvement. Ann Rheum Dis. 2002;61:682–686
  99. Medsger TA, Masi AT. Survival with scleroderma. II. A life-table analysis of clinical and demographic factors in 358 male U.S. veteran patients. J Chronic Dis. 1973;26:647–660
  100. Medsger TA, et al. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971;75:369–376
  101. Hong P, et al. Erectile dysfunction associated with scleroderma: a case-control study of men with scleroderma and rheumatoid arthritis. J Rheumatol. 2004;31:508–513
  102. Nowlin NS, et al. Impotence in scleroderma. Ann Intern Med. 1986;104:794–798
  103. Nehra A, et al. Systemic sclerosis and impotence: a clinicopathological correlation. J Urol. 1995;153:1140–1146
  104. Steen V. Sexual dysfunction and pregnancy in systemic sclerosis. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 319–330
  105. Bhadauria S, et al. Genital tract abnormalities and female sexual function impairment in systemic sclerosis. Am J Obstet Gynecol. 1995;172(2 Pt 1):580–587
  106. Englert H, et al. Reproductive function prior to disease onset in women with scleroderma. J Rheumatol. 1992;19:1575–1579
  107. Steen VD, et al. Pregnancy in women with systemic sclerosis. Arthritis Rheum. 1989;32:151–157
  108. Steen VD, Medsger TA. Fertility and pregnancy outcome in women with systemic sclerosis. Arthritis Rheum. 1999;42:763–768
  109. Black CM, Stevens WM. Scleroderma. Rheum Dis Clin North Am. 1989;15:193–212
  110. Weiner SR. Organ function: sexual function and pregnancy. In:  Clements P,  Furst D editor. Systemic sclerosis. Baltimore: Williams & Wilkins; 1995;p. 483–499
  111. Averbuch-Heller L, Steiner I, Abramsky O. Neurologic manifestations of progressive systemic sclerosis. Arch Neurol. 1992;49:1292–1295
  112. Herrick A. Nervous system involvement in systemic sclerosis. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 309–317
  113. Farrell DA, Medsger TA. Trigeminal neuropathy in progressive systemic sclerosis. Am J Med. 1982;73:57–62
  114. Klimiuk PS, et al. Autonomic neuropathy in systemic sclerosis. Ann Rheum Dis. 1988;47:542–545
  115. Medsger TA. Systemic sclerosis and Raynaud syndrome. In:  Koopman WJ,  Boulware DW,  Heudebert GR editor. Clinical primer of rheumatology. Philadelphia: Lippincott Williams and Wilkins; 2003;p. 171–181
  116. Kuwana M, et al. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum. 1994;37:75–83
  117. Hu PQ, et al. Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis. Arthritis Rheum. 2003;48:1363–1373
  118. Satoh M, et al. Association of autoantibodies to topoisomerase I and the phosphorylated (IIO) form of RNA polymerase II in Japanese scleroderma patients. J Immunol. 1994;153:5838–5848
  119. Sacks DG, et al. Isolated pulmonary hypertension in systemic sclerosis with diffuse cutaneous involvement: association with serum anti-U3RNP antibody. J Rheumatol. 1996;23:639–642
  120. Reveille JD, Solomon DH. Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies. Arthritis Rheum. 2003;49:399–412
  121. Poormoghim H, et al. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum. 2000;43:444–451
  122. Fudman EJ, Golbus J, Ike RW. Scleromyxedema with systemic involvement mimics rheumatic diseases. Arthritis Rheum. 1986;29:913–917
  123. Kantor GR, et al. Scleromyxedema associated with scleroderma renal disease and acute psychosis. J Am Acad Dermatol. 1986;14(5 Pt 2):879–888
  124. Gabriel SE, et al. Scleromyxedema: a scleroderma-like disorder with systemic manifestations. Medicine (Baltimore). 1988;67:58–65
  125. Miralles GD, O'Fallon JR, Talley NJ. Plasma-cell dyscrasia with polyneuropathy. The spectrum of POEMS syndrome. N Engl J Med. 1992;327:1919–1923
  126. Bardwick PA, et al. Plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, M protein, and skin changes: the POEMS syndrome. Report on two cases and a review of the literature. Medicine (Baltimore). 1980;59:311–322
  127. Soubrier MJ, Dubost JJ, Sauvezie BJ. POEMS syndrome: a study of 25 cases and a review of the literature. French Study Group on POEMS Syndrome. Am J Med. 1994;97:543–553
  128. Jablonska S, Blaszczyk M. Scleroderma-like disorders. Semin Cutan Med Surg. 1998;17:65–76
  129. Jablonska S, Blaszczyk M. Differential diagnosis of systemic sclerosis-like disorders. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 99–120
  130. Venencie PY, et al. Scleredema: a review of thirty-three cases. J Am Acad Dermatol. 1984;11:128–134
  131. Cowper SE, Bucala R. Nephrogenic fibrosing dermopathy: suspect identified, motive unclear. Am J Dermatopathol. 2003;25:358
  132. McNeill AM, Barr RJ. Scleromyxedema-like fibromucinosis in a patient undergoing hemodialysis. Int J Dermatol. 2002;41:364–367
  133. Streams BN, et al. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol. 2003;48:42–47
  134. Swartz RD, et al. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med. 2003;114:563–572
  135. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol. 2003;15:785–790
  136. Perazella MA, Ishibe S, Reilly RF. Nephrogenic fibrosing dermopathy: an unusual skin condition associated with kidney disease. Semin Dial. 2003;16:276–280
  137. Jimenez SA, et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum. 2004;50:2660–2666
  138. Lacour JP, et al. Fibroblastic rheumatism: clinical, histological, immunohistological, ultrastructural and biochemical study of a case. Br J Dermatol. 1993;128:194–202
  139. Vignon-Pennamen MD, et al. Fibroblastic rheumatism. J Am Acad Dermatol. 1986;14:1086–1088
  140. Pedersen JK, Poulsen T, Horslev-Petersen K. Fibroblastic rheumatism: a Scandinavian case report. Ann Rheum Dis. 2005;64:156–157
  141. Janin-Mercier A, et al. Immunohistologic and ultrastructural study of the sclerotic skin in chronic graft-versus-host disease in man. Am J Pathol. 1984;115:296–306
  142. Wolff D, et al. Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease. Bone Marrow Transplant. 2002;29:357–360
  143. Moreno JC, et al. Bullous scleroderma-like changes in chronic graft-versus-host disease. J Eur Acad Dermatol Venereol. 2003;17:200–203
  144. Furst DE, et al. A syndrome resembling progressive systemic sclerosis after bone marrow transplantation. A model for scleroderma?. Arthritis Rheum. 1979;22:904–910
  145. Siimes MA, Johansson E, Rapola J. Scleroderma-like graft-versus-host disease as late consequence of bone-marrow grafting. Lancet. 1977;2:831–832
  146. Wigley F, Hummers L. Managment: holistic approach to systemic sclerosis. A Physician's approach. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 371–384
  147. Rosenkranz S, et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med. 2003;139:871–873
  148. Clements P, Medsger TA, Feghali CA. Cutaneous involvement in systemic sclerosis. In:  Clements P,  Furst D editor. Systemic sclerosis. Philadelphia: Lippincott Williams and Wilkins; 2004;p. 129–150
  149. Tashkin DP, Elashoff R, Clements PJ, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354:2655–2666
  150. How can treatment of systemic sclerosis be improved? By setting up a national database of all cases and entering patients into trials. UK Scleroderma Study Group. BMJ. 1998;317:294–295
  151. Furst D, Pope J, Clements P. Systemic sclerosis. In:  Tugwell P, et al. editor. Evidence-based rheumatology. London, UK: BMJ Books; 2004;p. 443–483
  152. van den Hoogen FH, et al. Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial. Br J Rheumatol. 1996;35:364–372
  153. Pope JE, et al. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. Arthritis Rheum. 2001;44:1351–1358
  154. Casas JA, et al. 5-Fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study. Ann Rheum Dis. 1990;49:926–928
  155. Lin AT, Clements PJ, Furst DE. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis. Rheum Dis Clin North Am. 2003;29:409–426
  156. Binks M, et al. Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease. Ann Rheum Dis. 2001;60:577–584
  157. McSweeney PA, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes. Blood. 2002;100:1602–1610
  158. Furst DE. Stem cell transplantation for autoimmune disease: progress and problems. Curr Opin Rheumatol. 2002;14:220–224
  159. Ziesche R, et al. A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 1999;341:1264–1269
  160. Polisson RP, et al. A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels. J Rheumatol. 1996;23:654–658
  161. Black CM, et al. Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 1999;42:299–305
  162. Clements PJ, et al. High-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42:1194–1203
  163. Seibold JR, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2000;132:871–879
  164. Rubens C, et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest. 2001;120:1562–1569
  165. Wax D, Garofano R, Barst RJ. Effects of long-term infusion of prostacyclin on exercise performance in patients with primary pulmonary hypertension. Chest. 1999;116:914–920
  166. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med. 2001;22:529–537
  167. Simonneau G, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800–804
  168. Olschewski H, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160:600–607
  169. Olschewski H, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322–329
  170. Channick RN, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:1119–1123
  171. Rubin LJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896–903
  172. Abrams D, Schulze-Neick I, Magee AG. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart. 2000;84:E4
  173. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med. 2000;343:1342
  174. Ghofrani HA, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002;360:895–900
  175. Wilkens H, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001;104:1218–1222
  176. Ghofrani HA, et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med. 2002;136:515–522
  177. Weimann J, et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology. 2000;92:1702–1712
  178. Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil—review of the literature. Eur J Med Res. 2002;7:435–446
  179. Sachse R, Rohde G. Tolerability and pharmacokinetics of multiple dose treatment with the new PDE5-inhibitor BAY 38-9456. in EULAR. 2000. Brussels.
  180. Vobig MA, et al. Retinal side-effects of sildenafil. Lancet. 1999;353:375

PII: S0738-081X(06)00096-4

doi: 10.1016/j.clindermatol.2006.07.004

Clinics in Dermatology
Volume 24, Issue 5 , Pages 374-392 , September 2006

Article Tools

* Image Usage & Resolution